Climb Bio

CLYM · NASDAQ

$10.80+$1.07 (+11.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $9.73

About CLYM

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Employees: 28
Headquarters: Wellesley Hills, Massachusetts
Listed: Aug 10, 2021
Sector: Health Care
Industry: Biotechnology
Website: climbbio.com

Leadership

Climb Bio executives
Name	Title	Since	Age
Douglas Williams	—	—	67
Aoife Brennan	—	2024	49
Susan Altschuller	—	—	44
Cindy Driscoll	—	—	59
Andrew Levin	—	2018	48
Stephen Thomas	—	—	36
Alexander Cumbo	—	—	54
Kimberlee Drapkin	—	—	57
Judith Dunn	—	—	62

Similar companies

Companies in the same industry as Climb Bio

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.